Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21165362 | 0.87 | NISCH (0.40) | CASP1NISCHMEN1KMT2ABLM | |
| SCHEMBL21165403 | 0.87 | NISCH (0.40) | CASP1NISCHMEN1KMT2ABLM | |
| SCHEMBL21165406 | 0.86 | — | — | |
| SCHEMBL21165466 | 0.86 | — | — | |
| SCHEMBL21165282 | 0.85 | MEN1 (0.40) | CASP1NISCHMEN1KMT2ABLM | |
| SCHEMBL21165360 | 0.85 | MEN1 (0.40) | CASP1NISCHMEN1KMT2ABLM | |
| SCHEMBL15078371 | 0.80 | CASP1 (0.37) | CASP1NISCHKMT2AAOC3 | |
| SCHEMBL15078415 | 0.80 | CASP1 (0.37) | CASP1NISCHKMT2AAOC3 | |
| SCHEMBL15078414 | 0.80 | CASP1 (0.37) | CASP1NISCHKMT2AAOC3 | |
| SCHEMBL21165465 | 0.78 | CASP1 (0.41) | CASP1NISCHMEN1KMT2ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | claimed |
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | STS, SULT2A1, SULT1A1 | CASP1 3875/4885NISCH 108/4885MEN1 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.